News

The Phase III trial is planned to be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation and will be led by principal investigator from University of

As part of the deal, KODE would secure up to $31m in development and sales milestones, plus royalties on net sales, while Agalimmune will have exclusive rights to

Reslizumab is the company’s investigational humanized monoclonal antibody (mAb), which targets interleukin-5 (IL-5), and is being reviewed as a potential treatment for patients with eosinophilic asthma, despite an

Olipudase alfa is being evaluated to treat nonneurological manifestations of ASMD, also known as Niemann-Pick disease type B, as opposed to type A, which is characterized by neurological

As recently reported at the American Society of Clinical Oncology (ASCO) annual meeting, results show a significant reduction in the Total Symptom Score (TSS) (the proportion of patients

The study, entitled "Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion" authored by Andreas Müssigbrodt et

The grant will help fund an examination of the interaction of over 1400 FDA-Approved drugs and drug-like compounds with a variety of bromodomains, and facilitate the creation of

This patent, with a priority date of 2008, covers screening mechanisms for identification of small molecules that can modulate the function of a nuclear receptor target that was

Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. A copy of the poster, entitled "Updated